Key result
Dexmedetomidine significantly reduced the postoperative incidence of acute kidney injury compared to placebo in pediatric patients undergoing cardiac surgery (OR 0.49).
Why the study?
Acute kidney injury is a common and adverse complication following pediatric cardiac surgery, and dexmedetomidine offers potential organ-protective features.
Does dexmedetomidine infusion reduce the incidence of acute kidney injury in pediatric patients undergoing cardiac surgery with cardiopulmonary bypass?
Meta-Analysis (n=630)
Does dexmedetomidine infusion reduce the incidence of acute kidney injury in pediatric patients undergoing cardiac surgery with cardiopulmonary bypass?
Odds Ratio: 0.49 (95% CI 0.33–0.73)
p-value: p=0.0004
Dexmedetomidine infusion, particularly when administered as a combination of intra- and postoperative therapy, significantly reduces the incidence of acute kidney injury in pediatric patients undergoing cardiac surgery with cardiopulmonary bypass.
No takes yet. Share an insight, caveat, or question.
Supports dexmedetomidine to lower AKI risk in pediatric cardiac surgery; strengthens Level 1 evidence for perioperative renoprotection.
Wang et al. (2022) conducted a meta-analysis in Acute kidney injury following cardiac surgery (n=630). Dexmedetomidine vs. Placebo was evaluated on Incidence of acute kidney injury (AKI) (OR 0.49, 95% CI 0.33-0.73, p=0.0004). Dexmedetomidine significantly reduced the postoperative incidence of acute kidney injury compared to placebo in pediatric patients undergoing cardiac surgery (OR 0.49).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: